730 filings
Page 2 of 37
424B4
t6ztessi3ljt2kikpqgl
26 Jan 24
Prospectus supplement with pricing info
5:30pm
8-K
lab9mznt6n zz7uj
26 Jan 24
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
8:00am
EFFECT
qxzigo
26 Jan 24
Notice of effectiveness
12:15am
S-1MEF
vhv3xq at54y5e
25 Jan 24
Registration of additional securities for an S-1
9:44pm
CORRESP
28vmhh4i2ekj3 en
24 Jan 24
Correspondence with SEC
12:00am
CORRESP
el26 l8xtkar
24 Jan 24
Correspondence with SEC
12:00am
8-K
hs1iyxtv2wjzd
11 Dec 23
Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting
6:30am
UPLOAD
7sul6e
5 Dec 23
Letter from SEC
12:00am
8-K
0x9q8w
30 Nov 23
Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role
5:28pm
8-K
qg32r7
9 Nov 23
Aptose Reports Results for the Third Quarter 2023
4:15pm
8-K
r4m vs5un
2 Nov 23
Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting
9:15am
8-K
61a3bv56npcn6
30 Oct 23
Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib
9:20am
8-K
aifwycej eye1xh00sv
26 Oct 23
Regulation FD Disclosure
10:12am
8-K
ra8fw 5k1ecty
23 Oct 23
Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th
8:00am
8-K
kgtm9s6wbo vjrr
16 Oct 23
Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference
8:00am